Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Articles

Page Path
HOME > Cancer Res Treat > Volume 56(3); 2024 > Article
Editorial Editor’s Note on Recent Journal Impact Factor of Cancer Research and Treatment
Yong Chan Ahnorcid
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2024;56(3):699-699.
DOI: https://doi.org/10.4143/crt.2024.619
Published online: July 9, 2024

Editor-in-Chief of Cancer Research and Treatment

Correspondence: Yong Chan Ahn, Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
Tel: 82-2-3410-2602 Fax: 82-2-6190-5882 E-mail: ahnyc@skku.edu
• Received: July 8, 2024   • Revised: July 9, 2024   • Accepted: July 9, 2024

Copyright © 2024 by the Korean Cancer Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 4,722 Views
  • 99 Download
  • 1 Web of Science
  • 1 Crossref
  • 1 Scopus
next
Clarivate recently released information on the 2022-2023’ journals’ performance [1]. Among several parameters, Journal Impact Factor (JIF), rank by JIF, and rank by Journal Citation Indicator (JCI) could serve our understanding how the journal’s performance is to be evaluated. Cancer Research and Treatment (CRT)’s JIF dropped from 4.6 to 4.1 this year, and, however, the rank by JIF was maintained in the second quartile (from 89/241, Q2, 63.3% to 91/322, Q2, 71.9%), and the rank by JCI was improved from the second quartile to the first quartile (from 83/318, Q2, 74.06% to 69/322, Q1, 78.73%), respectively (Fig. 1). Appropriate interpretation of these parameters needs understanding of a few recent changes in Clarivate’s policy. Last year’s noticeable change was limiting the article exposure duration of 3 years in calculating the number of citations. This change was to eliminate the advantages by longer exposure duration and higher chance for citation by the online journals. According to this change, CRT’s JIF dropped from 5.036 to 4.6 to 4.1 recently, and the average JIF of all oncology journals dropped from 7.896 to 7.4 to 6.4 during the past 2 years, respectively. Another important change made this year is inclusion of 80 Emerging Sources Citation Index (ESCI) journals to the journal list for the first time, and this partly explains the average JIF fall of all oncology journals from 7.4 to 6.4. Based on these understanding recent changes of CRT’s performance, simple drop of JIF seems not to be disappointed, but seems relieving and even promising sign for CRT’s future growth. All editors of CRT have focused and will continue to focus on providing informative, educative, and influential articles to the readers by selecting the “readable and citable manuscripts.”

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Fig. 1.
Recent parameters that Cancer Research and Treatment achieved based on Clarivate report. JCI, Journal Citation Indicator; JIF, Journal Impact Factor.
crt-2024-619f1.jpg
  • 1. Journal Citation Reports [Internet]. Philadelphia, PA: Clarivate; 2024 [cited 2024 Jul 1]. Available from: https://jcr.claivate.com

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • How to Achieve Further Progress of Journal of Korean Neurosurgical Society (JKNS) - Improve the Impact Factor (IF) and Maintain It Continuously
      Hee-Jin Yang
      Journal of Korean Neurosurgical Society.2024; 67(5): 489.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Editor’s Note on Recent Journal Impact Factor of Cancer Research and Treatment
      Cancer Res Treat. 2024;56(3):699-699.   Published online July 9, 2024
      Close
    • XML DownloadXML Download
    Editor’s Note on Recent Journal Impact Factor of Cancer Research and Treatment
    Image
    Fig. 1. Recent parameters that Cancer Research and Treatment achieved based on Clarivate report. JCI, Journal Citation Indicator; JIF, Journal Impact Factor.
    Editor’s Note on Recent Journal Impact Factor of Cancer Research and Treatment

    Cancer Res Treat : Cancer Research and Treatment
    Close layer
    TOP